3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
9
Nivolumab
5
tislelizumab
2
spartalizumab
2
belinostat
2
atezolizumab
2
Pemetrexed
2
Paclitaxel
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Cisplatin
2
tocilizumab
1
sargramostim
1
obinutuzumab
1
niraparib
1
naptumomab estafenatox
1
milademetan
1
epacadostat
1
enzalutamide
1
durvalumab
1
cabozantinib
1
bosutinib
1
Sorafenib
1
Sirolimus
1
Quality of Life
1
Plicamycin
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Immunotherapy, Adoptive
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Blood Component Removal
×
Genitourinary
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled